John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
Bionano Genomics
BNGO
$14.7M
| $274K | ﹤0.01% |
+177
| New | +$239K |
|
|
ONCR
2227
DELISTED
Oncorus, Inc.
ONCR
| $273K | ﹤0.01% |
153,626
+63,908
| +71% | +$179K |
|
2228
Alphatec Holdings
ATEC
$1.44B
| $271K | ﹤0.01% |
23,600
-42,900
| -65% | -$464K |
|
2229
Eledon Pharmaceuticals
ELDN
$282M
| $270K | ﹤0.01% |
68,486
-56,707
| -45% | -$220K |
|
|
KW
2230
DELISTED
Kennedy-Wilson Holdings
KW
| $270K | ﹤0.01% |
+11,075
| New | +$255K |
|
2231
Noble Corp
NE
$7.32B
| $270K | ﹤0.01% |
+7,700
| New | +$217K |
|
2232
Otter Tail
OTTR
$3.83B
| $270K | ﹤0.01% |
+4,318
| New | +$271K |
|
2233
Consolidated Water Co
CWCO
$482M
| $269K | ﹤0.01% |
24,325
+4,982
| +26% | +$50.5K |
|
2234
Green Brick Partners
GRBK
$3.16B
| $269K | ﹤0.01% |
+13,600
| New | +$315K |
|
2235
Esquire Financial Holdings
ESQ
$1.37B
| $266K | ﹤0.01% |
7,923
-2,206
| -22% | -$74.1K |
|
|
CBAY
2236
DELISTED
Cymabay Therapeutics
CBAY
| $266K | ﹤0.01% |
85,414
+57,314
| +204% | +$180K |
|
|
ONCT
2237
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $266K | ﹤0.01% |
9,551
+2,758
| +41% | +$100K |
|
2238
TTEC Holdings
TTEC
$69M
| $265K | ﹤0.01% |
3,213
-5,821
| -64% | -$467K |
|
|
ZIMV
2239
DELISTED
ZimVie
ZIMV
| $265K | ﹤0.01% |
+11,606
| New | +$273K |
|
|
TESS
2240
DELISTED
Tessco Technologies Inc
TESS
| $264K | ﹤0.01% |
43,757
-47,494
| -52% | -$284K |
|
2241
Ametek
AME
$55.4B
| $263K | ﹤0.01% |
1,973
-382,014
| -99% | -$51.3M |
|
2242
Portillo's
PTLO
$352M
| $263K | ﹤0.01% |
+10,721
| New | +$284K |
|
2243
Tredegar Corp
TG
$276M
| $263K | ﹤0.01% |
+21,929
| New | +$259K |
|
2244
VirnetX Holding Corp
VHC
$53.9M
| $263K | ﹤0.01% |
8,059
+6,311
| +361% | +$258K |
|
2245
Medpace
MEDP
$17.1B
| $262K | ﹤0.01% |
1,600
-31,408
| -95% | -$5.18M |
|
2246
SPS Commerce
SPSC
$2.9B
| $262K | ﹤0.01% |
1,997
-31,866
| -94% | -$3.99M |
|
|
NESR
2247
National Energy Services Reunited Corp
NESR
$3.38B
| $261K | ﹤0.01% |
+31,109
| New | +$296K |
|
|
SPPI
2248
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $261K | ﹤0.01% |
202,201
-273,548
| -57% | -$252K |
|
|
KNTE
2249
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $259K | ﹤0.01% |
+22,966
| New | +$253K |
|
|
NOVN
2250
DELISTED
Novan, Inc. Common Stock
NOVN
| $259K | ﹤0.01% |
65,831
-120,121
| -65% | -$442K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.